Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Saturday, 10 / 16 / 2021

Abstract

De novo Hepatocellular Carcinoma after Liver Transplantation

Sammy Saab*1,2Kali Zhou1, Edward K Changand Ronald W Busuttil2

1Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;

Abstract

Liver transplantation is the definitive therapy for patients with advanced liver disease and its complications. Patients who are transplanted with a diagnosis of hepatocellular carcinoma (HCC) are at risk of recurrent cancer, and these patients are monitored on a regular basis for recurrence. In contrast, de novo HCC following liver transplantation is a very rare complication, and recipients without HCC at the time of transplantation are not screened. We describe the clinical features of de novo HCC over a decade after achieving a sustained viral response with treatment of hepatitis C and two decades after liver transplantation. Our case highlights the necessity of screening for HCC in the post-transplant patient with advanced liver disease even after viral clearance.

Doi: 10.14218/JCTH.2015.00033
Journal of Clinical and Translational Hepatology 2015 vol. 3, 284-287  [
PDF Full-text]

 

 

 logo